Friday's Biotech/Pharma Stocks Trading; (OTCBB: AEMD), (BMY), (DNDN), (GSK)
Biotech/Pharma Approaches to Cancer Therapy Snapshot
Category: Investment, Biotech
Ideas get bigger when you share them...
Visit this company: www.aethlonmedical.com
Point Roberts, WA - August 15, 2011 - Investorideas.com , an investor research portal specializing in sector research including biotech and pharma stocks reports on trading and recent news for companies providing novel approaches to cancer therapy . In a roller coaster market of trading last week, several of the biotech/pharma stocks closed on the upside on Friday.
Analyst Jeffrey Holford of A Jefferies & Co told clients on Friday, "We believe that the sector (pharmaceuticals stocks ) will soon likely act as a safe haven once investors reposition portfolios for slower growth and increased uncertainty over government and corporate balance sheets. "
Aethlon Medical (OTCBB: AEMD) traded in a range of $0.0750 - 0.0780 on Friday .
The Company released a new investor slide show/ media player entitled A Novel Therapeutic Strategy to Address Cancer. According to the presentation , “The Aethlon Hemopuriﬁer® is the ﬁrst therapeutic candidate to eliminate cancer exosomes from circulation ,providing a therapeutic ﬁltration mechanism to remove cancer exosomes from the circulatory system, It allows selective exosome capture via unique high-mannose signatures resident on exosome surfaces
and provides access to the entire circulatory system. Exosomes can be accessed from entire circulatory system, which can pass through the Hemopuriﬁer® in as little as 15 minutes
The Hemopuriﬁer® therapy has the advantage of beingdelivered through the global infrastructure of dialysismachines that are already located in hospitals in clinics.
Bristol-Myers Squibb Company (NYSE: BMY) closed at $27.97, up 0.17 (0.61%) in Friday's trading . According to the company's Second Quarter report July 28 th , there are several key developments in its oncology divisions. In June, the Company entered into a clinical collaboration agreement with Roche to conduct a Phase I/II study to evaluate the safety and efficacy of the combination of YERVOY and vemurafenib in treating patients with metastatic melanoma.
In July, the Company announced a global agreement with Innate Pharma S.A., a biotech company in France, for the development and commercialization of IPH 2102, a novel immuno-oncology biologic in Phase I development.
Dendreon Corporation (NasdaqGS: DNDN) closed Friday at $10.44, up 0.07 (0.68%) on over 8 million shares. The Company reported Second Quarter results August 3 rd and noted, "Our accomplishments this year are foundational as we introduce an entirely new treatment paradigm for patients with advanced prostate cancer," continued Dr. Gold. "These position us well to realize the significant market potential of PROVENGE, and we have identified a solid and clear path to ensuring that the many men who can benefit from it have access to our life-extending drug."
GlaxoSmithKline (NYSE: GSK) ended trading on Friday at $41.30, up 0.49 (1.20%).
Biotech/Pharma Company Snapshot for Aethlon Medical (OTCBB: AEMD)
Visit the showcase page on Investorideas.com
Get added to the company's news alerts:
OTCBB:AEMD slide show / media - A Novel Therapeutic Strategy to Address Cancer
A Novel Therapeutic Strategy to Address Cancer - Presentation Transcript
1.A Novel Therapeutic Strategy to Address Cancer September 2011
2.Cancer is the leading cause of deathworldwide and accounted for 7.6 million deaths in 2008 alone
3.There were 12.7 million new cases of Cancer in 2008
4.Cancer deaths in the United States are expected to exceed 570,000 in 2011
5.In 2011, new cases of Cancer are expected to exceed 1,500,000 in the U.S.
6.Innovative strategies are needed to address Cancer progression mechanisms that are beyond the reach of current drug therapies
7.A therapeutic strategy that could inhibit the proliferation of immunosuppressive exosomes released by solid tumors, lymphomas and leukemias would fill a significant unmet medical need in cancer care
8.What are Exosomes?• Cancer cells, both in vivo and in vitro, have been demonstrated to release membranous structures, deﬁned as exosomes
9.Researchers have recently unveiled several roles that exosomes play in accelerating cancer progression
10.The resulting research publications are reporting that................
11.Exosomes cause apoptosis or programmed cell death of immune cells
12.Exosomes disrupt signaling of anti-cancer T cells
13.Exosomes contribute to tumor angiogenesis
14.Exosomes enhance the spread of tumor metastasis
15.The quantity of exosomes in circulation is indirect correlation with cancer progression
16.What if exosomes could be eliminated from circulation?
17.The Aethlon Hemopuriﬁer® The ﬁrst therapeutic candidate to eliminate cancer exosomes from circulation
18.The Aethlon Hemopuriﬁer®• Provides a therapeutic ﬁltration mechanism to remove cancer exosomes from the circulatory system• Allows selective exosome capture via unique high-mannose signatures resident on exosome surfaces
19.Providing access to the entire circulatory system• Exosomes can be accessed from entire circulatory system, which can pass through the Hemopuriﬁer® in as little as 15 minutes
20.Hemopuriﬁer® therapy has the advantage of beingdelivered through the global infrastructure of dialysismachines that are already located in hospitals in clinics
21.Our goal is to improve patient responsiveness to traditional chemotherapies and emerging classes of immune based therapies
22.To improve patient responsiveness without additional drug toxicity or interaction risks
23.In vitro binding of exosomes underlying the following cancers has been demonstrated• Breast• Ovarian• Colorectal• Lymphoma• Melanoma
24.Human Hemopuriﬁer® treatment experience already exists
25.The Hemopuriﬁer® has previously demonstrated the ability to reduce viral load in HIV and hepatitis C (HCV) infected individuals without the administration of antiviral drugs
26.A clinical study to evaluate the ability of the Hemopuriﬁer® to improve HCV drug therapy benefit is currently being conducted
27.The clinical application of the Hemopuriﬁer® in Cancer?
28.We are currently collaborating with candidate investigators to develop a clinical protocol to demonstrate the ability of our Hemopuriﬁer® to eliminate circulating cancer exosomes
29.We invite you to follow our efforts to improve cancer care AethlonMedical.com
30.Our mission is to create innovative devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions Thank You
Chairman, CEO8910 University Center Lane
San Diego , California92122jj@aethlonmedical.com
This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, and Aethlon Medical intends that such forward-looking statements be subject to the safe harbor created thereby. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including the company's ability to successfully obtain FDA and other regulatory approvals for the sale of its products, the capability of the Hemopuriﬁer® to reduce viral loads and other disease conditions or to identify or treat disease conditions such as cancer or Hepatitis-C, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, and the company's ability to raise capital when needed. Some information in this presentation, or on which this presentation is based, has been obtained from sources that Aethlon Medical, Inc., believes to be reliable and accurate. However, it has not been independently verified and no representation or warranty, express or implied, is made as to the accuracy or completeness of any information obtained from third parties. Such risks and uncertainties, including those discussed above, are more fully described in the Securities and Exchange Commission (SEC) reports ﬁled by Aethlon Medical, Inc., including its most recent annual report on Form 10-K. This presentation speaks only as of its date, and the company disclaims any duty to update the information herein. Further information is avail able by contacting the company or at the company's website at www.aethlonmedical.com.
James A. Joyce
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. AETHLON MEDICAL INC(OTC BB: AEMD ) Showcase biotech, biodefense and defense stock on Investorideas.com ( $one thousand five hundred per month, 200,000 144 shares )
OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - email@example.com
Source - Investorideas.com
This news is published on the Investorideas.com Newswire and its syndicated partner network
Get free news alerts:
Sign up here
Published at the Investorideas.com Newswire - Big ideas for Global Investors
Disclaimer/ Disclosure:The Investorideas.com newswire is a third party publisher of news as well as creates original content as a news source. Original content created by investor ideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and global syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions and advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers.
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.